Sakharnyy diabet: reperfuzionnye oslozhneniya i problemy kardioprotektsii


Cite item

Full Text

Abstract

Рост заболеваемости сахарным диабетом (СД), отмечаемый во всем мире, сопровождается ростом числа больных СД, подвергающихся процедурам реваскуляризации по поводу ишемической болезни сердца (ИБС). В настоящее время больные СД составляют не менее 20% от общего числа реваскуляризированных больных ИБС. К сожалению, как при применении аортокоронарного шунтирования (АКШ), так и при использовании чрескожной транслюминальной коронарной ангиопластики (ЧТКА), частота внутригоспитальных осложнений, послеоперационная долгосрочная смертность и потребность в повторных реваскуляризациях среди больных СД достоверно выше, чем у лиц без диабета. У больных с "оглушенным" миокардом терапевтические возможности представляются более широкими. Хотя принципиально предотвратить развитие "оглушения" в ситуации хронической ишемии/реперфузии пока не представляется возможным, вполне вероятно уменьшить проявления "оглушения" и попытаться предотвратить переход хронического "оглушения" в "гибернацию". С этой точки зрения особый интерес представляют препараты, обладающие способностью воздействовать непосредственно на реперфузионный компонент формирования "оглушения" миокарда.Учитывая то, что в настоящее время триметазидин MB является практически единственным клинически апробированным препаратом, активно воздействующим на электролитные механизмы развития "оглушения" миокарда, представляется весьма перспективным использование триметазидина MB у больных с повторно возникающими эпизодами ишемии/реперфузии для снижения риска развития "оглушения" миокарда и перехода "оглушения" миокарда в его "гибернацию". Особый эффект использование триметазидина MB можно ожидать у больных, предрасположенных к развитию клеточных электролитных нарушений на фоне ИБС. К таким больным в первую очередь относятся больные СД.

About the authors

I. I Dedov

ГУ Эндокринологический научный центр РАМН, Москва

A. A Aleksandrov

ГУ Эндокринологический научный центр РАМН, Москва

References

  1. Koon-Hou Mak, David P. Faxon. Clinical studies on coronary revascularization in patients with type 2 diabetes. Eur Heart J 2003; 24: 1087–103.
  2. Stein B, Weintraub W.S, Gebhart S.S.P et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995; 91: 979–89.
  3. Kip K.E, Faxon D.P, Detre K.M el al. Coronary angioplasty in diabetic patients: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996; 94: 1818–25.
  4. Morris J.J, Smith L.R, Jones R.H et al. Influence of diabetes and, mammary artery grafting on survival after coronary bypass. Circulation 1991; 84 (suppl. 3): Ш275–84.
  5. Smith R, Harrell F.E, Rankin J.S et al. Determinants of early versus late cardiac death in patients undergoing coronary artery bypass graft surgery. Circulation 1991; 84 (suppl. III): 111245–53.
  6. Alderman E.L, Corley S.D, Fisher L.D et at. The CASS Participating Investigators and Staff. Five - year angiographic follow - up of factors associated with progression of coronary artery disease in the Coronary Artery Surgery Study (CASS). J Am Coll Cardiol 1993; 22: 1141–54.
  7. Herlitz J. Karlson B.W, Wognsen G. et al. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabet Care 1996; 19: 698–703.
  8. Barsness G.W, Peterson E.D, Ohman E.M et al. Relationship between diabetes mellitus and long - term survival after coronary bypass and angioplasty. Circulation 1997; 96: 2551–6.
  9. Elezi S, Kastrati A, Pache J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866–73.
  10. Levine O.N, Jacobs A.K, Keeler G.P et al. for the CAVEAT-I Investigators. Impact of diabetes mellitus on percutaneous revas - cularization (CAVEAT-I). Am J Cardiol 1997; 79: 748–55.
  11. The BARI Investigators, Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation. Circulation 1997; 96: 1761–9.
  12. Detre K.M, Lombardero M.S. Brooks M.M el al., for the Bypass Angioplasty Revascularization Investigaton Investigators, The effect of previous coronary - artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. N Engl J Med 2000; 342: 989–97.
  13. Labinaz M, Madan M, O'Shea J el al. Comparison of one - year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet II/IIIa Receptor with Integrilin Theprapy [ESPRIT] trial). Am J Cardiol 2002; 90: 585–90.
  14. Rozeuman Y, Sapoznikov D, Gotsman M.S. Restenosis and progression of coronary disease after balloon angioplasty in patients with diabetes mellitus. Clin Cardiol 2000; 23: 890–4.
  15. Rozenman Y el al. Long - term angiographic follow - up of coronary balloon angioplasty in patients with diabetes mellitus; a clue to the explanation of the results of the BARI study. Balloon Angioplasty Revascularization Investigation, 3 Am Coll Cardiol 1997; 30: 1420–5.
  16. Bourassa M.G et al. Is a strategy of intended incomplete percutaneous transluminal coronary angioplasty revascularization acceptable in nondiabetic patients who are Candidates for coronary artery bypass graft surgery? The Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 1999; 33: 1627–36.
  17. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessed disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997; 96: 1761–9.
  18. O'Neill W.W. Multivessel balloon angioplasty should be abandoned in diabetic patients! J Am Coll Cardiol 1998; 31: 20–2.
  19. Mak K.H, Moliterno D.J, Granger C.B et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997; 30: 171–9.
  20. Hasdai D, Granger C.B, Srivatsa S et al. Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-llb angioplasty substudy. J Am Coll Cordial 2000; 35: 1502–12.
  21. Detre K.M, Guo P, Holubkov R et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of teh Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999; 99: 633–40.
  22. Weintraub W.S, Stein B, Kosinski A et al. Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cordiol 1998; 31: 10–9.
  23. Halon D.A, Flugelman M.Y, Merdler A et al. Similar late revascularization rates 10 to 12 years after angioplasty or bypass surgery for multivessel coronary artery disease: a report from the Lady Davis Carmel Medical Center (LDCMC) Registry. Am J Cardiol 2000; 86: 1131–4.
  24. Barsness G.W, Peterson E.D, Ohman E.M et al. Relationship between diabetes meliitus and long - term survival after coronary bypass and angioplasty. Circulation 1997; 96: 2551–6.
  25. Gum P.A, O'Keefe J.H.Jr, Sorkon A.M et al. Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation 1997; 96: ll–7–ll–10.
  26. Niles N.W, Mc Grath P.D, Malenka D et al. Survival of patients with diabetes and ultivessel coronary artery disease after surgical or percutaneous coronary revascularization: results from a large regional prospective study. J Am Coll Cardiol 2001; 37: 100S–15.
  27. Dzavik V, Ghali W.A, Norris С et al. Long - term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. Am Heart J 2001; 142: 119–26.
  28. Feit F, Brooks M.M, Sopko G et al. Long-Term Clinical Outcome in the Bypass Angioplasty Revascularization Investigation Registry. Circulation 2000; 101: 2795–802.
  29. Thourani V.H, Weintraub W.S, Stein В et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999; 67: 1045–52.
  30. Herlitz J, Wognsen G.B, Emanuelsson H et al. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 1996; 19: 698–703.
  31. Lawrie G, Morris G, Gleser D. Influenceof diabetes mellitus on results of coronary artery bypass surgery. JAMA 1986; 256: 2967–71.
  32. The BARI Investiators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000; 35: 1122–9. Serruys P.W, de Jaegere P, Kiemeneij F et al. A compan'son of balloon - expandable - stent implantation with balloon angioplasty in patients with coronary artery disease. Nengl J Med 1994; 331–489–95.
  33. Van Belle E, Bauters C, Hubert E et al. Restenosis rates in diabetic patients. A comparison of coronary stenting and balloon angioplasty in native coronary vessels. Circulation 1997; 96: 1454–60.
  34. Savage M.P, Fischman D.L, Siota P et al. Coronary intervention in the diabetic patient: improved outcome following stent implantation versus balloon angioplasty [abstract]. J Am Coll Cardiol 1№; 29: 188A.
  35. Mehilli J, Kastrati A, Dirschinger J et al. Comparison of stenting with balloon angioplasty for lesions of small coronary vessels in patients with diabetes mellitus. Am J Med 2002; 112: 13–8.
  36. Van Belle E, Perie M, Braune D et al. Effects of coronary stenting on vessel patency and long - term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 2002; 40: 410–7.
  37. Suselbeck T, Latsch A, Sirf H et al. Role of vessel sire as a predictor for the ccurrence of in - stent restenosis in patients with diabetes mellitus. Am J Cardiol 2001; 88: 243–7.
  38. Carrozza Jr.J.P, Kuntz R.E, Fishman R.F et al. Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Intern Med 1993; 118: 344–9.
  39. Lau K.W, Ding Z.P, Johan A et al. Midterm angiographic outcome of single - vessel intracoronary stent placement in diabetic versus nondiabetic patients: a matched comparative study. Am Heart J 1998; 136: 150–5.
  40. Elezi S, Kastrati A, Pache J et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1993; 32: 1866–73.
  41. Schofer J, Schloter M, Rau Tetal, Influence of treatment modality on angiographic outcome after coronary stenting in diabetic patients: a controlled study. J Am Colt Cordial 2000; 35: 1554–9.
  42. Abizaid A, Kornowski R, Mintz O.S et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. J Am Colt Cardiol 1998; 32: 584–9.
  43. Marso S.P, Ellis S.G, Bhatt P.L et al. The stenting in diabetics debate: insight from the large GUSTO lIb experience wit extended follow - up. Circulation 1998; 98: l–78.
  44. Carrozza J.P, Ho K.K.L, Neimann D et al. Diabetes mellitus is associated with adverse 6-month angiographic and clinical outcome following coronary stenting. Circulation 1998; 98: 1–79.
  45. Sousa J.E, Costa M.A, Abizaid A.C et al. Sustained suppression of neolntfmal proliferation by sirolimus - etutini stents one - year angiographic and Intravascular ultrasound follow - up. Circulation 2001; 104: 2007–11.
  46. Kleiman N.S, Lincoff A.M, Kereiakes D.J et al. Diabetes mellitus, glycoprotein Iib/IIIa blockade, and heparin. Evidence for a complex interaction in a multicenter trial. Circulation 1998; 1912–20.
  47. Marso S.P, Lincoff A.M, Ellis S.G et al. Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus. Results of the EPISTENT (Evaluation of Platelet Iib/IIIa inhibitor for Stenting Trial) Diabetic Substudy. Circulation 1999; 100: 2477–84.
  48. Velianou J.L, Mathew V, Wilson S.H et al. Effect of abciximab on late adverse events in patients with diabetes mellitus undergoing stent implantation. Am J Cardiol 2000; 86: 1063–8.
  49. Abizaid A, Costa M.A, Centemero M et al. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. Circulation 2001; 104: 533–8.
  50. Loop F.D, Lytle B.W, Cosgrove D.M et at. Reoperation for coronary atherosclerosis. Changing practice in 2,509 consecutive patients. Annals Surg 1990; 212: 378–86.
  51. Lytle B.W; Loop F.D, Cosgrove D.M. Fifteen hundred coronary reoperations: results and determinants of early and lute survival. 3 Thoracic Cardiovasc Surg 1987; 93: 847–59.
  52. Lytle B.W, Loop F.D, Taylor P.C et at. The effect of coronary reoperation on the survival of patients with stenoses in saphenous vein bypass grafts to coronary arteries. J Thoracic Cardiovasc Surg 1993; 105: 605–14.
  53. Stephan W.J; O'Keefe J.H, Piehler J.M et al. Coronary angioplasty versus repeat coronary artery bypass grafting for patients with previous bypass surgery. J Am Coll Cardiol 1996; 28: 1140–6.
  54. Ernst S.M, van der Feltz Т.А, Ascoop C.A et al. Percutaneous transluminal coronary angioplasty in patients with prior coronary artery bypass grafting. Long - terrm results. J Thoracic Cardiovasc Surg 1987; 93: 268-75.
  55. Pick A.W. Mullany C.J, Orszulak Т.А et al. Third and fourth operations for myocardial ischemia: short - term results and long - term survival. Circulation 1997; 96: 26–31.
  56. Hannan E.L, Kilburn H, O'Donnell J.F et al. Adult open - heart surgery in New York state. An analysis of risk factors and hospital mortality rates. JAMA 1990; 264: 2768–74.
  57. Kornowski R, Mintz G.S, Lansky A.J et al. Paradoxic decreases in atherosclerotic plaque mass in insulin - treated diabetic patients. Am J Cordial 1998; 98: 1298–304.
  58. Rozenman Y, Sapoznikov D, Mosseri M et al. Long - term angiographic follow - up of coronary balloon angioplasty in patients with diabetes mellitus. A clue to the explanation of the results of the BARI study. J Am Coll Cardiol 1997; 30: 1420–5.
  59. Van Belle E, Ketelers R, Bauters С et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-nionlh angiographic follow - up. Circulation 2001; 103: 1218–24.
  60. Mathew V, Clavell A.L, Lennon R.J et al. Percutaneous coronary interventions in patients with prior coronary artery bypass surgery; Changes in patient characteristics and outcome during two decades. Am J Med 2000; 108; 127-35.
  61. Kаrаm С, Fajadet J, Beauchet A et al. Nine - year follow - up of balloon - expandable Palmaz-Schatz stent in patients with single - vessel disease. Cathet Cardiovasc Intervent 2000; 50: 170–4.
  62. Osende J.L, Badimon J.J, Fuster V et al. Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. J Am Coll Cardiol 2001; 38: 1307–12.
  63. Braunwald E, Kloner R.A. The stunned myocardium: prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146–9.
  64. Bolli R. Mechanism of myocardial "Stunning". Circulation 1990; 82: 723–38.
  65. Bolli R. Myocardial "stunning" in man. Circulation 1992; 86: 1671–91.
  66. Heyndrickx G.R, Millard R.W, Mc Ritchie R.J et al. Regional myocardial functional and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975; 56: 978–85.
  67. Bolli R, and Mc Cay. Use of spin traps in intact animals undergoing myocardial ischemia/reperfusion: a new approach to assessing the role of oxygen radicals in myocardial "stuning". Free Radical Res Commun 1990; 9: 169–80.
  68. Sekili S, P.B Mc Cay, X-Y Li et al. Effect of adenosine on myocardial "stunning" in the dog. Circ Res 1995; 76: 82–94.
  69. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 1999; 79 (2): 610–31
  70. Kusuoka H, Porterfield J.K, Weisman H.F et al. Pathophysiology and pathogenesis of stunned myocardium. Depressed Ca+ activation of contraction as a conseguence of reperfusion - induced cellular calcium overload in ferret hearts. J Clin Invest 1987; 79: 950–61.
  71. Mc Donald K.S, Mammen P.P.A, Moss R.L et al. Decreased myofilament Ca + sensitivity alone may not account for the depressed contractile state of stunned myocardium (Abstract) Circulation 1993; 88 (Suppl. 1): 1–130.
  72. Gao W.D, Atar D, Liu Y et al. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res 1997; 80: 393–9.
  73. Van Eyk J.E, Powers F, Law W et al. Breakdown and release of myofilament proteins during ischemia and ischemia/reperfusion in rat hearts. Identification of degradation products and effects on the pCa - force relation. Circ Res 1998; 82: 261–71.
  74. Bolli R, Jeroudi M.O, Patel B.S et al. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: avidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ Res 1989; 65: 607–22.
  75. Bolli R, Jeroudi M.O, Patel B.S et al. Direct evidance that oxygen - derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci USA 1989; 86: 4695–9.
  76. Bolli R, Patel B.S, Jeroudi M.O et al. Demonstration of free radical generation in the "stunned" myocardium of intact dogs with the use of the spin trap alpha - phenyl N-tert - butyl nitrone. J Clin Invest 1988; 82: 476–85.
  77. Li X.Y, Mc Cay P.B, Zughaib M et al. Demonstration of free radical generation in the "stunned" myocardium in the conscious dog and identification of major differences between conscious and open - chest dogs. J Clin Invest 1993; 92: 1025–41.
  78. Sekili S, Mc Cay P.B, Li X-Y et al. Direct evidence that the hydroxyi radical plays a pathogenetic role in myocardial "stunning" in the conscious dog and that stunning can be markedly attenuated without subsequent adverse effects. Circ Res 1993; 73: 705–23.
  79. Sun J.Z, Kaur H, Halliwell B et al. Use of aromatic hydroxylation of phenylalanine to measure production of hydroxyl radicals after myocardial ischemia in vivo: direct evidence for a pathogenetic role of the hydroxyl radical in myocardial stanning. Circ Res 1993; 73: 534–49.
  80. Bolli R, Zhu W.X, Hartley C.J et al. Attenuation of dysfunction in the postischemic "stunned" myocardium by dimethylthiorea. Circulation 1987; 76: 458–68.
  81. Murry C.E, Richard V.J, Jennings R.B, Reimer K.A. Free radicals do not cause myocardial stunning after four 5 minute coronary occiusions (Abstract). Circulation 1989; 80 (suppl. II): II–296.
  82. Przyklenk K, Kloner R.A. Superoxide dismutase plus catalase improves contractile function in the canine model of the "stunning" myocardium. Circ Res 1986; 58: 148–56.
  83. Gross G.J, Farber N.E, Hardman H.F, Warltier D.C. Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs. Am J Physiol 1986; 250 (Heart Circ. Physiol. 19): H372–7.
  84. Koerner J.E, Anderson B.A, Dage R.C. Protection against postischemic myocardial dysfunction in anesthetized rabbits with scavengers of oxygen - derived free radicals: superoxide dismutase plus catalase, N-2- mercaptopropionyl glycine and captopril. J Cardiovasc Pharmacol 1991; 17: 185–91.
  85. Suzuki S.M, Kaneko D.C, Chapman Dhalla N.S. Alterations in cardiac contractile proteins due to oxygen free radicals. Biochim Biophys Acta 1991; 1074: 95–100.
  86. Kaneko M, Beamish R.E, Dhalla N.S. Depression of heart sarcolemmal Ca2+-pump activity by oxygen free radicals. Am J Physiol 1989; 256 (Heart Circ. Physiol. 25): H368–74.
  87. Kaneko M, Elimban V, Dhalla N.S. Mechanism for depression of heart sarcolemmal Ca 2+ pump by oxygen free radicals. Am J Physiol 1989; 257 (Heart Circ. Physiol. 26): H804–11.
  88. Hears D.J. Stunning: a radical review. Cardiovasc Drugs Ther 1991; 5: 853–76.
  89. Kim M-S, Akera T. O2 free radicals: cause of ischemia reperfusion injury to cardiac Na+-K+-ATPase. Am J Physiol 1987; 252 (Heart Circ. Physiol. 21): H252–7.
  90. Mayers M, Farhangkhoee P, Karmazyn M. Hydrogen peroxide induced impairment of post - ischemic ventricular function is prevented by the sodium - hydrogen exchange inhibitor HOE 642 (cariporide). Cardiovasc Res 1998; 40: 290–6.
  91. Lazdunski M, Frelin C, Vigne P. The sodium/hydrogen exchange system in cardiac cells: its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH. J Mol Cell Cardiol 1985; 17: 1029–42.
  92. Uizdunski M, Frelin C, Vigne P. The sodium/hydrogen exchange system in cardiac cells: its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH. J Mol Cell Cardiol 1985; 17: 1029–42.
  93. Piwnica-Worms D, Jacob R, Shigcto N et al. Na/H exchange in cultured heart cells: secondary stimulation of electrogenic transport during recovery from intracellular acidosis. J Mol Cell Cardiol 1986; 18: 1109–16.
  94. Kim D, Cragoe E.J, Smith T.W. Relations among sodium pump inhibition, Na-Ca and Na-H exchange activities and Ca-H interactions in cultured chick heart cells. Circ Res 1987; 60: 185–93.
  95. Siffert W, Akkerman J.W.N. Na+/H+ exchange and Ca2+ influx. FEBS Lett 1989; 259: 1–4. ??. Aronson P.S. Kinetic properties of the plasma membrane Na+/H= exchanger. Annu Rev Physiol 1985; 47: 545–60.
  96. Paris S, Pouyssegur J. Biochemical characterization of the amiloride - sensitive Na+/H+ antiport in Chinese hamster lung fibroblasts. J Biol Chem 1983; 258: 3503–8.
  97. Aronson P.S, Nee J, Suhm M.A. Modifier role of internal H + in activating the Na+-H+ exchanger in renal microvillus membrane vesicles. Nature 1982; 299: 161–3.
  98. Koike A, Akita T, Hotta Y et al. Protective effects of dimethyl amiloride against postischemic myocardial dysfunction in rabbit hearts: phosphorus 31-nuclear magnetic resonace measurements of intracellular pH and cellular energy. J Thorac Cardiovasc Surg 1996; 765–75. ???. Schmig A, Richardt G. Cardiac sympathetic activity in myocardial ischemia: release and effects of noradrenaline. Basic Res Cardiol 1990; 85 (Suppl. 1): 9–30.
  99. Puceat M, Clement-Chomienne O, Terzic A, Vassort G. a1-Adrenoreceptor and purinoreceptor agonists modulate Na-H antiport in single cardiac cells. Am J Physiol 1993; 264: H310–9.
  100. Lazdunski M, Frelin C, Vigne P. The sodium/hydrogen exchange system in cardiac cells: its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH. J Mol Cell Cardiol 1985; 17: 1029–42.
  101. Cross H, Radda G, Clarke K. The role of Na+/K+ATPase activity during low flow ischemia in preventing myocardial injury: a -'P. "Na and S7Rb NMR spectroscopic study. Magn Res Med 1995; 34: 673–85.
  102. Ladilov Y, Siegmund B, Piper H. Protection of reoxygenated cardiomyocytes aganst hypercontracture by inhibition of Na+/H+ exchange. Am J Physiol 1995; 268: H1531–9.
  103. Hendrikx M, Mubagwa K, Verdonck F et al. New Na(T)-H+ exchange inhibitor HOE-694 improves postischemic function and high - energy phosphate resynthesis and reduces Caz+ overload in isolated perfused rabbit heart. Circulation 1594; 89: 2787–98.
  104. Liu H. Cala P.M. Anderson S.E. Ethylisopropylamiloride diminishes changes in intracellular Na Ca and pH in ischemic newborn myocardium. J Mol Cell Cardiol 1997; 29: 2077–86.
  105. Tani M, Neely J. Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts: possible involvement of H+-Na+ and Na* Ca2+ exchange. Ore Res 1989; 65: 1045–56.
  106. Weiss R, Lakatta E, Gerstenblith G. Effects of amiloride on metabolism and contractility during reoxygenation in perfused rat hearts. Circ Res 1990; 66: 1012–22.
  107. Haigney M, Lakatta E, Stern M, Silverman H. Sodium channel blockade reduces hyposic sodium loading and sodium - dependent calcium loading. Circulation 1994; 90: 391–9.
  108. Van Emous J.G, Schreur J.H, Ruigrok T.J, Van Echteld C.J. Both Na+-K+ ATPase and Na+-H+ exchanger are immediately active upon post - ishemic reperfusion in isolated rat hearts, J Mol Cell Cardiol 1998; 30: 337–48.
  109. Steenbergen C, Perlman M, London R, Murphy E. Mechanism of preconditioning: ionic alterations. Circ Res 1993; 72: 112–25.
  110. Kitakaze M, Weisfeldt M.L, Marban E. Acidosis during early reperfusion prevents myocardial stunning in perfused ferret hearts. J Clin Invest 1988; 82: 920–7.
  111. Kusuoka H, De Hurtado M, Marban E. Role of sodium/calcium exchange in the mechanism of myocardial stunning: protective effect of reperfusion with high sodium solution. J Am Coll Cardiol 1993; 21: 240–8.
  112. Bond J, Herman B, Lemasters J. Protection by acidotic pH against anoxia/reoxygenation injury to neonatal cardiac myocytes. Biochem Biophys Res Comra 1991; 179: 798–803.
  113. Kaplan S, Ynag H, Gilliam D et al. Hypercapnic acidosis and dimethyl amiloride reduce reperfusion induced cell death in ischaemic ventricular myocardium. Cardiovasc Res 1995; 29: 231–8.
  114. Harper I.S, Bond J.M, Chacon E et al. Inhibition of Na+/H+ exchange preserves viability, restores mechanical function, and prevents the pH paradox in reperfusion injury to rat neonatal myocyies. Basic Res Cardiol 1993; 88: 430–42.
  115. Ibuki C, Hearse D, Avkiran M. Mechanisms of antifibrillatory effect of acidic reperfusion: role of perfusate bicarbonate concentration. Am J Physiol 1993; 264: H783–90.
  116. Bolli R. Mechanism of myocardial "stunning". Circulation 1990; 82: 723–38. ???. Gao W, Atar D, Liu Y, Perez N, Murphy A, Marban E. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res 1997; 80: 393–9.
  117. Mellgren R.L. Canine cardiac calcium - dependent proteases: resolution of two forms with different requirements for calcium. FEBS Lett 1980; 109: 129–33.
  118. Mellgren R.L, Murachi T. Intracellular Calcium-Dpendent Proteolysis. Boca Raton, FL: CRC, 1990.
  119. Di Lisa F, De Tullio R, Salamino F et al. Specific degradation of troponin T and I by m - calpain and its substrate phosphorylation. Biochem J 1995; 308: 57–61.
  120. Garrozza J.P, Bentivegna Jr.L.A, Williams C.P et al. Decreased myofilament responsiveness in myocardial stunning follows transient calcium overload during ischemia and reperfusion. Circ Res 1992; 71: 1334–40.
  121. Marban E, Kitakaze M, Kusoka H et al. Chacko. Intracellular free calcium concentration measured with 19F NMR spectroscopy in intact ferret hearts. Proc Natl Acad Sci USA 1987; 84: 6005–9.
  122. Miller W.P, Mc Donald K.S, Moss R.L. Onset of reduced Ca2+ sensitivity of tension during stunning in porcine myocardium. J Mol Cell Cardiol 1996; 28: 689–97.
  123. Gerd Heusch, Rainer Schulz, and Shahbudin H. Rahimtoola. Myocardial hibernation: a delicate balance. Am J Physiol Heart Circ Physiol 2005; 288: H984–99.
  124. Hearse D. Ischaemia, reperfusion and cardioprotection: successes and failures in the journey from molecule to man. Eur Heart J 2001; 3: C11–21.
  125. Hears D.J. Reperfusion of the ischemic myocardium. J Mol Cell Cardiol 1977; 9: 605–16.
  126. Shen Y-T, Vatner S.F. Mechanism of impaired myocardial function during progressive coronary stenosis in conscious pigs:hibernation versus stunning? Circ Res 1995; 73: 479–88.
  127. Gerd Heusch, Rainer Schulz, Shahbudin H. Rahimtoola. Myocardial hibernation: a delicate balance. Am J Physiol Heart Circ Physiol 2005; 288: H984–99.
  128. Ganguly P.K, Pierce G.N, Dhalla K.S, Dhalla S.N. Defective sarcoplasmic reticular calcium transport In diabetic cardiomyopathy. Am J Physiol 1983; 244: E528–35.
  129. Makino N, Dhalla K.S, Elirnban V, Dhalla S.N. Sarcolemmal Ca2+ transport in streptozotocin - induced diabetic cardiomyopathy in rats. Am J Physiol 1987; 253: E202–7.
  130. Russ M. Reinauer H, Eckel J/ Diabetes - induced decrease in the mRNA coding for sarcoplasmic reticulum Ca2+-ATPase in adult rat cardiomyocytes, Biochem Btophys Res Cornmun 1991; 178: 905–12.
  131. Nobe S, Aomine M, Artia M et al. Chronic diabetes rnellitus prolongs action potential duration of rat ventricular muscles: circumstantial evidence for impaired Ca2+ channel. Cardiovasc Res 1990; 24: 381–9.
  132. Rerce G.N, Ohalla S.N. Cardiac myoftorillar ATPase activity in diabetc rats. J Mol Cell Cardiol 1981; 13: 1063–9.
  133. Ohara T, Sussman К.Е, Drazrin B. Effect of diabetes on cytosolic fRee Ca2+ and Na+-K+-ATPase in rat aorta. Diabetes 1991; 40: 1560–3.
  134. Nakagawa M, Kabayashi S, Klmura 1, Kimura M. Diabetic state - induced modification of Ca, Mg, Fe, and Zn content of skeletal, cardiac and smooth muscles. Endocrinol Jpn 1989; 36: 795–807.
  135. Kobayashi S, Fujftiara M, Hoshino N et al. Diabetic state - induced activation of calcium - activated neutral proteinase in mouse skeletal muscle. Endocrinol Jpn 1989; 36: 833–44.
  136. Taira Y, Hata T, Ganguly P.K et al. increased sarcolemmal Ca2+ transport activity in skeletal muscle of diabetic rats. Am J Physiol 1991; 260: Ј626–32.
  137. Ganguly P.K, Matrw S, Gupta M.P et al. Calcium pump activity of sarcoplasmic reticulum in diabetic rat skeletal muscle. Am J Physiol 1986; 251: E515–23.
  138. Levy J, Grunberger G, Karl I, Gavin J.R 111. Effects of food restriction and insulin treatment on (Ca2+ + Mg2+)-ATPase response to insulin in kidney basolateral membranes of non - insutin - dependent diabetic rats. Metabolism 1990; 39: 25–33.
  139. Sahai A, Qanguly P.K. Lack of response of (Ca2+ + Mg2+) – ATPase natriuretic peptide in basolateral membranes from kidney cortex of chronic diabetic rats, Biochem Biophys Res Comrnun 1990; 169: 537–44.
  140. Sluder R.K, Ganas L. Effect of diabetes on hormone - stimulated and basal hepatocyte calcium metabolism. Endocrinology 1989; 125: 2421–33.
  141. Chan K.M, Junger K.D. The effect of streptozocin - induced diabetes on the plasma membrane calcium uptake activity of rat liver. Diabetes 1984; 33: 1072–7.
  142. Zemel M.B, Sowers J.R, Shehin S et al. Impaired calcium metabolism associated with hypertension in Zucker obese rats. Metabolism 1990; 39: 704–8.
  143. Levy J, Sowers, Zemel M.B. Abnormal Ca2+-ATPase activity in erythrocytes of non iinsulin - dependent diabetic rats. Horm Metab Res 1990; 22: 136–40.
  144. Pierce G.N, Afzal N, Kroeger E.A et al. Cataract formation is prevented by administration of verapamil to diabetic rats. Endocrinology 1989; 125: 730–5.
  145. Cowan T, Levy J, Dunbar J. Role of cell calcium metabolism in cataract formation of diabetic rats (Abstract). Clin Res 1992; 40: 239.
  146. Agrawal D.K, Mc Neil J.H. Vascular responses to agonists in rat mesenteric - artery from diabetic rats. Can J Ptiystol Pharmacol 1987; 65: 1484–90.
  147. Pieper G.M, Grass G.J. Diabetes enhances vasoreactivity to calcium entry Mockers, Artery 1989; 16: 263–71.
  148. Afzal N, Ganguly P.K, Dhalla K.S et al. Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 1988; 37: 936–42.
  149. Dhalla N.S, Pierce G.N, Innes I.R, Beamish R.E. Pathogenesis of cardiac - dysfunction in diabetes mellltus. Can J Cardiol 1985; 1: 263–81.
  150. Bergh C.H, Hjalmarson A, Holm G et al. Studies on calcium exchange in platelets in human diabetes. Eur J Clin Invest 1988; 18: 92–7.
  151. Davis F.B, Davis P.J, Bias S.D, Schoenl M. Action of tone - chain fatty acids in vitro on Ca2+-stimulatable, Mg2+-dependent ATPase activity in human red cell membranes. Biocriem J 1987; 248: 511–1.
  152. Levy J, Reid I, Halstad L et al. Abnormal cell calcium concentration in cultured hone cells obtained from femurs of obese and non - insulindependent diabetic rats. Calcif Tissue Int 1989; 44: 131–7.
  153. Maser R.E, Wolfson S.K, Ellis D et al. Cardiovascular disease and arterial calcification In insulin - dependent diabetes rnellitus: interrelations and risk factor profiles. Pittsburgh Epidemiology of Diabetes Comolications Study-V. Artehoscler Thromb l991; 11: 958–65.
  154. Fleckstein A, Frey M, Fleckstein-Grum G. Antihypertensive and arterial anticalcinotic effects of calcium antagonists. Am J Cardiol 1986; 57: 1D–10D.
  155. Katz M.A, Mc Neill G. Defective vasodilation response to exercise in cutaneous precapillary vessels in diabetic humans. Diabetes 1987; 36: 1386–96.
  156. Baldini P, Incerpi S, Lambert-Gardini S et al. Membrane IDDM alterations and Na+-pumping activity in erythrocytes from IDDM and NIDDM subjects. Diabetes 1989; 38: 825–31.
  157. Schaefer W, PriBen J, Manntiold R. Gries A.F. Ca 2+ + Mg2+-ATPase activity of human red blood cells in healthy and diabetic volunteers. Klin Wochenschr 1987; 65: 17–21.
  158. Zemel M.B, Bedford B.A, Zemel P.C et al. Altered cation transport in non - lrsulin - denendent diabetic hypertension: effect of dietary calcium. J Hypertension 1988; 6 (suppl. 4): 228–30.
  159. Rahmani-Jourdheuil D, Mourayre Y, Vague P et l. In vivo insulin effect on ATPase activities in erythrocyte membrane from insulin - dependent diabetics. Diabetes 1987; 36: 991–5.
  160. Ishii H, Umeda F, Hashimoto T, Hawata H. Changes in phosphoinositide turnover, Ca2+ mobilization, and protein phosphorylation in platelets from NIDDM patients. Diabetes 1990; 39: 1561–8.
  161. Mazzanti L, Rabini R.A, Faloia E et al. AJtered cellular Ca2+ and Na+ transport in diabetes mellitus. Diabetes 1990; 39: 850–4.
  162. Ishii H, Umeda F, Hashimoto T, Nawata H. Iricreased intracellular calcium mobilization in platelets from patients with type 2 (non - insulin - dependent] diabetes mellitus, Diabetologia 1991; 34: 332–6.
  163. Tschope O, Rosen P. Gries F.A. Increase in the cytosolic concentration of calcium in platelets of diabetics type II. Thromb Res 1991; 62: 421–8.
  164. Levy J, Stem Z, Gutman A et al. Plasma calcium and phosphate levels in an adult non - insulin - dependent diabetic population. Calcif Tissue Int 1986; 39: 316–8.
  165. Sorva A, Tilvis R.S. Low serum ionized to total calcium ratio; association with geriatric diabetes mellitus and with otter cardiovascular risk factors? Gerontology 1990; 36: 212–6.
  166. Pedrazzoni M, Ciotti G, Pioii G et al. Osteocalcin levels in diabetic subjects. Calcif Tissue Int 1989; 45: 331–6.
  167. Levy J, Teitelbaum S.L, Gavin J.R III et al. Bone calcification and calcium homeostasis in rats with non - insulin - dependent diabetes induced by streptozotocin. Diabetes 1985; 34: 365–72.
  168. Levy J, Zemel M.B, Sowers J.R. Role of calcium metabolism in abnormal glucose metabolism and diabetic hypertension. Am J Med 1989; 87 (suppl. 6A): 7–15.
  169. Levy J, Aviodi L.V, Roberts M.L, Gavin J.R III. (Na+ + K+)-ATPase activity in kidney basolateral membranes of non - insulin - dependent diabetic rats. Biochem Biophys Res Commun 1986; 139: 1313–9.
  170. Resh M.D. Insulin action on the (Na+ + K+)-ATPase in: Czech M.P, editor. Molecular basis of insulin action. New York: Plenum Press 1985; 451–65.
  171. Kalofoutis A, Lekakis J. Changes of platelet phospholipids in diabetes mellitus. Diabetologia 1981; 21: 540–3.
  172. Y. Kuwahara T, Yanagishita N. Konno T. Katagiri Changes in microsomal membrane phospholipids and fatty acids and in activities of membrane - bound enzyme in diabetic rat heart. Basic Res Cardiol 1997; 92: 214–22.
  173. Byington P.R. Isradipine, raised glycosylated haemoglobin, and risk of cardiovascular events. Lancet 1997; 350: 1075–6.
  174. Alderman M et al. Calcium antagonists and cardiovascular events in patients with hypertension and diabetes. Lancet 1998; 351: 216–7.
  175. Braunwald E, Rutherford I.D. Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol 1986; 8: 1467–70.
  176. Dispersyn G.D, Ausma J, Thone F et al. Cardiomyocyte remodelling during myocardial hibernation and atrial fibrillation; prelude to apoplosis. Cardiovasc Res 1999; 43: 947–57.
  177. Borgers M, Thone F, Wouters L et al. Structural correlates of reginal myocardial dysfunction in patients with critical coronary artery stenosis: chronic hibernation? Cardiovasc Pathol 1993; 2: 237–45.
  178. Shahbudin H. Rahimtoola, MB, FRCP, MACP. Myocardial hibernation: clinical manifestations and importance. Dialog Cardiovascular Med 1997; 2 (2): 59–75.
  179. Borgers Mand Ausma J. Structural aspects of the chronic hibernating myocardium in man. Basic Res Card 90: 44–6.
  180. Ross J.Jr. Myocardial perfusion - contraction matching. Implications coronary heart disease and hibernation. Circ 1991; 83: 1076–108.
  181. Rahimtoola S.H. A perspective on the three multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation 1985; 72 (Suppl. V): V-123–35.
  182. Taegtmeyer H, Overturt M.L. Effects of moderate hypertension on cardiac function and metabolism in the rabbit. Hypertension 1988; 11: 416–26.
  183. Sack M.N, Rader Т.А, Park S et al. Mitochondrial fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996; 94: 2837–42.
  184. Bishop S.P, Altschuld R.A. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol 1970; 218: 153–9.
  185. Heusch G, What are the underlying mechanisms of myocardial hibernation? Dialog Cardiovasc Med 1997; 2 (2): 79–83.
  186. Schulz R, Post H, Neumann T et al. Progressive loss of perfusion - contraction matching during sustained moderate ischemia in pigs. Am J Physiol Mean Circ Physiol 2001; 28: <Ш1945-Н 1953.
  187. Heusch G, Rose J, Skyschally A et al. Calcium respon siveness in regional myocardial short - term hibernation and stunning in the in situ porcine heart - inotropic responses to postextrasystolie poteniiation and intracoronary calcium. Circulation 1996; 93: 1556–66.
  188. Vikhliantsev I.M, Podlubnaia Z.A. Adaptive behavior of titin isoforms from skeletal and cardiac muscles of ground squirrels (Citellus undulates) during hibernation. Biofizika 2004 May-Jun; 49 (3): 430–5.
  189. Thijssen V.L.J.L, Borgers M, Lenders M-H et al. temporal and spatial variations in structural protein expression during the progression from stunned to hibernating myocardium. Circulation 2004; 110: 3313–21.
  190. Depre C, Kim S-J, Jhon A.S et al. Vatner. Program of cell survival underlying human and experimental hibernating myocardium. Circ Res 2004; 95: 433–40.
  191. Kim S-J, Peppas A, Hong S-K et al. Persistent stunning induces myocardial hibernation and protection: flow/function and metabolic mechanisms. Circ Res 2003; 92: 1233–9.
  192. Bax J.J, Poldermans D, van der Wall E.E. Evaluation of hibernating myocardium. Heart 2004; 90: 1239–40.
  193. Bonow R.O. Identification of viable myocardium. Circulation 1996; 94: 2674–80.
  194. Camici P.G, Gropler R.J, Jones T et al. The impact of myocardial blood flow quantitation with PET on the understanding of cardiac diseases. Eur Heart J 1996; 17: 25–34.
  195. Schelbert H.R. Positron emission Tomography for the assessment of myocardial viability. Circulation 1991; 84 (Suppl. I): I-122–I-131.
  196. Gallagher K.P, Osakada G, Matsuzaki M et al. Nonuniformity of inner and outer systolic wall thickening in conscious dogs. Am J Physiol Heart Circ Physiol 1985; 249: H241–8.
  197. Robert O, Bonow, M.D. How is it possible to diagnose myocardial hibernation? Dialogues in Cardiovasc Med 1997; 2 (2): 84–91.
  198. Mudge G.H.Jr, Mills R.M.Jr, Taegtmeyer H et al. Alterations of myocardial amino acid metabolism in chronic ischemic heart disease. J Clin Invest 1976; 58: 1185–92.
  199. Bonow R.O, Dilsizian V, Cuocolo A, Bacharach S.L. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation 1991; 83: 26–37.
  200. Bito V, Hetnzel F.R, Weldemann F et al. Cellular mechanisms of contractile dysfunction in hibernating myocardium. Cellular remodeling in hibernation. Circ Res 2004; 94: 794–801.
  201. Kaprielian R.R, Gunning M, Dupond E et al. Downregulation of immunodelectable connexin43 and decreased gap junction size in the pathogenesis of chronic hibernation in the human left ventricle. Circulation 1998; 97: 651–60.
  202. Allman K.C, Shaw L.J, Hachamovitch R, Udelson J.E. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta - analysis. J Am Cardiol 2002; 1151–8.
  203. Myers M.L, Bolli R, Lekich R.F el al. Enhancement of recovery of myocardial function by oxygen free radical scavengers after reversible regional ischemia. Circulation 1985; 72: 915–21.
  204. Bolli R, Jeroudi M.D, Patel B.S et al. Direct evidence that oxygen - derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci USA 1989; 86: 4695–9.
  205. Jeroudi M.O, Triana F.J, Patel B.S et al. Effect of superoxide dismutase and catalase, given separately, on myocardial "stunning." Am J Physiol 1990; 259: H889–901.
  206. Gross G.J, Farber M.E, Hardman H.F et al. Beneficial actions of superoxide dismutase and catalase in stunned myocardium of dogs. Am J Physiol 1986; 250: H372–7.
  207. Bolli R.R, Patel B.S, Jeroudi M.O et al. Demonstration of free radical generation in "stunned" myocardium of intact dogs with the use of the spin trap alpha - phenyl N-tertiary butyl nitrone. J Clin Invest 1988; 82: 476–85.
  208. Bolli R, Jeroudi M.O, Patel B.S et al. Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion: evidence that myocardial "stunning" is a manifestalion of reperfusion injury. Circ Res l989; G5: 607–22.
  209. Przyklenk K, Kloner R.A. Reperfusion injury by oxygen - free radicals? Effect of supeioxide dismutase plus catalase, given at the time of reperfusion, on myocardial infarct size, contractile Sanction, coronary microvasculature, and regional myocardial blood flow. Circ Res 1989; 64: 86–96.
  210. Flaherty J.T, Pitt B, Gruber J.W et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation 1994; 89: 1982–91.
  211. Przyklenk K, Kloner R.A. Calcium antagonists and the stunned myocardium. J Cardiovasc Pharmacol 199l; 18 (supp1. 10): S93–101.
  212. Przyklenk K, Ghafari G.B, Eitzman D.T et al. Nifedipine administered post reperfusion ablates systolic contractile dysfunction of postischemic "stunned" myocardium. J Am Coll Cardiol 1989; 13: 1176–83.
  213. Sheiban L, Tonni S, Marini A et al. Clinical and therapeutic implications of chronic left ventricular dysfunction in coronary artery disease. Am J Cardiol 1995; 73: 23E–30E.
  214. Rinaldi C.A, Linka A.Z, Masaini N.D et al. Randomized, double - blind crossover study to investigate the effects of amlodipine and isosorbide mononitrate on the time course and severity of exercise - induced myocardial stunning. Circulation 1998; 98: 749–56.
  215. Ertl G and Hu K. Anti - ischemic potential of drugs related to the reninangiotensin system. J Cardiovasc Pharmacol 2001; 37: 311–20.
  216. Westin W and Mullane K. Does captopril attenuate reperfusion - induced myocardial dysfunction by scavenging free radicals? Circulation 1988; 77: 130–9.
  217. Ehring T, Baumgart D, Krajcar M et al. Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation J 1994; 90: 1363–85.
  218. Nakai T, Satoh K, Kosugi T et al. Participation of angiotensin II and bradykinin in contractile function in dog stunned myocardium. Eur J Pharmacol 1999; 382: 187–96.
  219. Zhu B, Sun Y, Sievers R.E et al. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia - reperfusion. J Am Coll Cardiol 2000; 35: 787–95.
  220. Matsui H, Barry W, Livsey C, Spitzer K. Angiotensin II stimulates sodium - hydrogen exchange in adult rabbit ventricular myocytes. Cardiovasc Res 1995; 29: 215–21.
  221. Grace A.A, Metcalfe J.C, Weissberg P.L et al. Angiotensin II stimulates sodium - dependent proton extrusion in perfused ferret heart. Am J Physiol 1996; 270: C1687–94.
  222. Skolnick R.L, Lilwin S.B, Barry W.H, Spitzer K.W. Effect of ANG II on pH,, Ca" and contraction in rabbit ventricular myocytes from infarcted hearts. Am J Physiol 1998; 275: HI788–97.
  223. Wang Q.D, Sjoquist P.O. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts. Eur J Pharmacol 1999; 380: 13–21.
  224. Dorge H, Behrends M, Schulz E et al. Attenuation of myocardial stunning by the AT, receptor antagonist candesartan. Basic Res Cardial 1999; 94: 208–14.
  225. Yahiro E, Ideishi M, Wang L.X et al. Reperfusion - induced arrhythmias are suppressed by inhibition of the angiotensin II type 1 receptor. Cardiology 2003; 99: 61–7.
  226. Louch W.E, Ferrier G.R, Howlett S.E. Losartan improves recovery of contraction and inhibits transient inward current in a cellular model of cardiac ischemia and reperfusion. J Pharmacol Exp Ther 2000; 295: 697–704.
  227. Ford W.R, Clanachan A.S, Lopaschuk G.D et al. Intrinsic ANG II type 1 receptor stimulation contributes to recovery of postischemic mechanical function. Am J Physiol 1998; 274: H1524–31.
  228. So T, Nakashima Y, Imamura M, Arakawa K. Effects of local inhibition of the cardiac renin - angiotensin system with CV-11974 in a canine ischaemia - reperfusion model. Clin Exp Pharmacol Physiol 1998; 18: 503–9.
  229. Schomig A, Richardt G. Cardiac sympathetic activity in myocardial ischemia: release and effects of noradrenaline, Basic Res Cardiol 1990; 85 (Suppl. 1): 9–30.
  230. Corr P.R, Yamada K.A, Da Torre S.D. Modulation of alfa - adrenergic receptors and their intracellular coupling in the ischemic heart. Basic Res Cardiol 1990; 85 (Suppl. 1): 31–45.
  231. Price D.T, Lefkowitz R.J, Caron M.G et al. Localization of mRNA for three distinct alfa1-ailrenergic receptor subtypes in human tissues: implications for human ii - adrenergic physiology. Mol Pharmacol 1994; 45: 171–5.
  232. Yokoyama H, Yasutake M, Avkiran M. a - Adrenergic stimulation of sarcolemmal Na+/H+ exchanger activity in rat ventricular myocytes: evidence for selective mediation by the alfa1A-adrenoceptor subtype. Circ Res 1998; 82: 1078–85.
  233. Lagadic-Gossmann D, Vaughan-Jones R.D. Coupling of dual acid extrusion in the guinea - pig isolated ventricular myocyte to alfa1- and beta - adrenoceptors. J Physiol 1993; 464: 49–73.
  234. Wu M.L, Tseng Y.Z. The modulatory effects of endothelin-1, carbachol and isoprenaline upon Na +-H+ exchange in dog cardiac Purkinje fibres. J Physiol 1993; 471: 583–97.
  235. Wu M.L, Vaughan-Jones R.D. Effect of metabolic inhibitors and second messengers upon Na+-H+ exchange in the sheep cardiac Purkinjie fibre. J Physiol 1994; 478: 301–13.
  236. Karmazyn M. Amiloride enhances postischemic ventricular recovery, possible role of Na- H exchange. Am J Physiol 198R; 255: H608–15.
  237. Karmazyn M, Ray M, Haist J.V. Comparative effects of NaVH"1 exchange inhibitors against cardiac injury produced by ischemia/repcrfusion, hypos ia/reoxygenati on, and the calcium parados. J Cardiovasc Pharmac 1993; 21: 172–8.
  238. Shimada Y, Hearse D.J, Avkiran M. Impact of extracellular buffer composition on cardioprotective efficacy of Na'/H" exchanger inhibitors. Am J Physiol 1996; 270: ИЙ92–700.
  239. Klein H, Bohle R, Picfl S et al. Time - dependent protection by Na+/H+ exchange inhibition in a regionally ischemic, reper - fused porcine heart preparation with low residual blood How. J Mol Cell Cardiol 1998; 30: 795–801.
  240. Rohmann S, Weygandt H, Minck K. Preischaemic as well as postischaemic application of a Na+/H+ exchange inhibitor reduces infarct size in pigs. Cardiovasc Res 1995; 30: 945–51.
  241. Garcia-Dorado D, Gonzalez M, Barrabes J et al. Prevention of ischemic rigor contracture during coronary occlusion by inhibition of Na+-H+ exchange. Cardiovasc Res 1997; 35: 80–9.
  242. Miura T, Ogawa T, Suzuki K et al. Infarct size limitation by a new Na^-H* exchange inhibitor, HOE-642: difference from preconditioning in the role of protein kinase C. J Am Coll Cardiol 1997; 29: 693–701.
  243. Hano O, Silverman H, Blank P et al. Nicardipine prevents calcium loading and 'oxygen paradox" in anoxic single rut myocytes by a mechansism independent of calcium channel blockade. Circ Res 1991; 69: 1500–5.
  244. Murphy E, Perlman M, London R.E, Steenbergen C. Ainilo - ride delays the ischemia - induced rise in cylosolit free calcium. Circ Res 1991; 68: 1250–8.
  245. Karmazyn M. The myocardial sodium - hydrogen exchanger (NHE) and its role in mediating ischemic and reperfusion injury. Keio J Med 1998; 47: 65–72.
  246. Anderson S, Murphy E, Steenbergen C et al. Na-H exchange in myocardium; effects of hypoxia and acidification on Na and Ca. Am J Physiol 1990; 259: CT40–8.
  247. Theroux P, Chaitman B.R, Danchin N, Erhardt L et al. Jessel Inhibition of the Sodium-Hydrogen Exchanger with Cariporide to Prevent Myocardial Infarction in High-Risk Ischemic Situations. Main Results of the GUARDIAN Trial. Circulation 2000; 26: 3032–8.
  248. Birand A, Kudaiberdieva G.Z, Batyraliev T.A et al. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disesase after percutaneous transluminal angioplasty. Angiology 1997; 48 (5): 413–22.
  249. Sowers J.R. Insulin resistance, hyperinsulinemia, dyslipidemia, hypertension and accelerated atherosclerosis. J Clin Pharmacd 1992; 32: 529–35.

Copyright (c) 2006 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies